Abstract
In this article, we review the literature on the current advances in targeted therapies for metastatic gastric cancer aimed at improving patient care. We conclude that the key to guiding targeted therapy is individual biomarkers, which are not completely elucidated. HER2 overexpression is the only predictive biomarker currently in use. Furthermore, it is necessary to understand that gastric tumors are heterogeneous; therefore, is impossible to evaluate a novel biological compound without evaluating personal biomarkers. The selection of patients who are able to receive each treatment is paramount for improving advanced gastric cancer survival and reducing unnecessary costs.
Keywords:
current advances; gastric cancer; gastric cancer therapy; patient care; targeted therapy.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Angiogenesis Inhibitors / pharmacology
-
Angiogenesis Inhibitors / therapeutic use
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use*
-
Clinical Trials as Topic
-
Drug Discovery
-
ErbB Receptors / antagonists & inhibitors
-
Humans
-
Molecular Targeted Therapy*
-
Neoplasm Metastasis
-
Patient Care
-
Protein Kinase Inhibitors / pharmacology
-
Protein Kinase Inhibitors / therapeutic use
-
Quality Improvement
-
Receptor, ErbB-2 / antagonists & inhibitors
-
Stomach Neoplasms / drug therapy*
-
Stomach Neoplasms / metabolism
-
Stomach Neoplasms / mortality
-
Stomach Neoplasms / pathology*
-
Treatment Outcome
Substances
-
Angiogenesis Inhibitors
-
Antineoplastic Agents
-
Protein Kinase Inhibitors
-
ErbB Receptors
-
Receptor, ErbB-2